Phase 3 Trial to Uncover Therapeutic Potential of 5-HT6 Antagonist Masupirdine to Treat Alzheimer Agitation Louie Pasculli

Published Date: 04 Dec 2025

A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New surgical method shows promising results for cervical cancer treatment

2.

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

3.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

4.

Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer

5.

Can Prior Authorization Be Better With Artificial Intelligence?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot